Psoriasis Treatment: Evidence-Based Options for Every Severity

Understanding Your Psoriasis Before Choosing Treatment

Psoriasis is not just a skin problem. It is a chronic, immune-mediated systemic disease that happens to show its most visible symptoms on the skin.^[4] Understanding this distinction shapes every treatment decision you make. For a broader look at how inflammatory skin diseases compare, see our guide to types of skin rashes in adults.

The Immune Cycle Behind Psoriatic Plaques

In healthy skin, new cells form deep in the epidermis (the outer layer) and slowly migrate to the surface over about 28 days. In psoriatic skin, that cycle speeds up dramatically because an overactive immune response pushes keratinocytes (the main skin cells) to multiply far faster than normal.^[5] Imagine a factory running 24-hour shifts when it only has storage for one shift's output: the cells pile up faster than your body can shed them, forming the thick, scaly plaques that define the condition.

Research over the past two decades has identified the IL-23/IL-17 axis as the central driver of psoriatic inflammation.^[7] Think of it as a chain reaction: dendritic cells (the skin's early-warning sensors) release IL-23, a chemical messenger that switches on Th17 cells, which are immune cells that drive inflammation. Those cells then pour out IL-17A and other cytokines (inflammatory signaling proteins) that speed up skin cell production and call in even more immune cells.^[7] TNF-alpha, another inflammatory signal, amplifies this cascade and carries the effects beyond the skin into the rest of the body.^[8] This is why psoriasis treatment has shifted from simply slowing skin cells to targeting specific immune pathways. Plaque psoriasis accounts for the majority of cases.^[9] For a full breakdown of every variant, see our guide to types of psoriasis.

Matching Treatment to Your Severity

Dermatologists classify psoriasis severity using body surface area (BSA) involvement and quality-of-life impact:

• Mild: Less than about 5% BSA, manageable with topical treatments alone^[50]
• Moderate: 5 to 10% BSA, may need phototherapy or combination approaches^[50]
• Severe: Greater than 10% BSA or significant quality-of-life impairment, typically requires systemic therapy^[10]

But severity is not just about surface area. The International Psoriasis Council also considers patients eligible for systemic therapy if they have psoriasis in high-impact areas regardless of BSA, or if topical therapy has failed.^[10] Psoriasis on the face, hands, feet, or genitals can devastate quality of life even at low BSA percentages.^[11]

Topical Treatments: The Foundation for Mild to Moderate Psoriasis

If you have ever stood at the pharmacy shelf staring at tubes of cream wondering which one will actually help, you are starting where most people with psoriasis start. Topical therapies remain the first line of psoriasis treatment for most patients. In real-world practice, about 87% of patients with mild to moderate disease have been prescribed topical therapies and/or phototherapy at diagnosis.^[12] The key is choosing the right agent for the right body area. For a deep dive on specific products and prescribing patterns, see our guide to topical medications and treatment approaches.

Corticosteroids and Vitamin D Analogues

Topical corticosteroids are the most widely prescribed psoriasis treatment. They work by slipping inside skin cells and dialing down the genes that produce inflammatory signals, acting a bit like a thermostat that turns down an overheated immune response.^[13] Potency is typically classified into four tiers, from mild (such as hydrocortisone 1%) to very high potency (clobetasol propionate 0.05%).^[13]

Higher-potency steroids clear plaques faster but carry greater risk of skin thinning, reduced elasticity, and barrier dysfunction with prolonged use, which is a bit like pressing harder on the gas pedal: you get there faster, but the engine wears out sooner.^[14] This is why dermatologists match potency to body area: very high potency for thick plaques on elbows and knees, mild to moderate for the face and skin folds. For more on steroid safety concerns, see our guide on topical steroid withdrawal.

Vitamin D analogues like calcipotriene slow keratinocyte proliferation and promote normal cell differentiation. A systematic review of 37 RCTs confirmed calcipotriol is effective for mild to moderate plaque psoriasis and comparable to potent topical corticosteroids.^[15] They work through a different mechanism than steroids, which makes them ideal combination partners.

The practical takeaway: Combination calcipotriene-betamethasone foam is more effective than either component used separately, and combining it with NB-UVB phototherapy produced a complete response in 74.6% of patients versus 46.8% with phototherapy alone.^[16]

Newer Non-Steroidal Topicals: Tapinarof and Roflumilast

Two recent FDA approvals have expanded the topical toolkit beyond steroids and vitamin D:

• Tapinarof (Vtama): An aryl hydrocarbon receptor agonist approved for plaque psoriasis. In Japanese phase 3 trials, PASI 75 response rose from 37.7% at week 12 to 79.9% at week 52, with continued improvement over a year of use.^[17] It carries no steroid-related side effects.
• Roflumilast cream (Zoryve): A PDE4 inhibitor that reduces inflammation without steroids. In the DERMIS-1 and DERMIS-2 phase 3 trials, IGA success at 8 weeks reached 42.4% and 37.5% versus about 6% on vehicle.^[18] It is also approved for use in intertriginous areas (skin folds).

Both agents offer steroid-free alternatives for long-term topical management, which matters for patients concerned about steroid side effects on sensitive areas. Topical selection also depends on body area, with solutions and foams preferred for the scalp and gentler agents for the face and folds.^[13]

Topical treatments typically show initial improvement within 2 to 4 weeks, with maximum benefit at 8 to 12 weeks. But topicals alone may not be enough, and when plaques cover more than 10% of your body or stop responding to creams, the next step usually involves light or pills.

Phototherapy and Systemic Medications

When creams stop being enough, the next steps on the treatment ladder use either targeted light or pills you swallow. These approaches treat psoriasis from a broader vantage point because phototherapy calms inflammation through controlled UV exposure, while systemic medications adjust the immune system from the inside out.

Phototherapy: NB-UVB, Excimer, and PUVA

Narrowband UVB (NB-UVB) at 311 to 313 nm is the most common form of phototherapy for psoriasis. It calms overactive T cells (immune cells driving inflammation) and slows the rapid skin cell turnover that builds up plaques, working a bit like turning down both the heat and the speed dial on a runaway oven. In the STEPIn study, NB-UVB cleared at least 90% of plaques (a benchmark called PASI 90) by week 52 in 42% of patients with new, moderate-to-severe plaque psoriasis.^[3]

For localized plaques, the 308 nm excimer lamp delivers targeted UVB to affected areas while sparing healthy skin, working like a spotlight rather than a floodlight. Combined with topical agents like 10% liquor carbonis detergens (a refined coal tar solution), excimer lamp therapy achieved a 75% reduction in scalp psoriasis severity in 69.2% of patients versus 28.6% with excimer alone in a single randomized trial.^[33]

PUVA (psoralen plus UVA) is an older approach that remains effective and is even of superior efficacy to some biologics, but high cumulative PUVA exposure significantly increases skin cancer risk.^[19] Most dermatologists now prefer NB-UVB as the first-line phototherapy option. Home NB-UVB units have made phototherapy more accessible, with efficacy comparable to office-based treatment and improved compliance.^[20]

Traditional Oral Systemics: Methotrexate, Cyclosporine, Acitretin

About 20% of patients with psoriasis experience moderate-to-severe symptoms and are considered suitable for systemic therapy.^[22] For a broader comparison of how systemic options are used across inflammatory skin diseases, see our atopic dermatitis treatments guide. Three older oral agents have decades of clinical experience behind them:

• Methotrexate: An immunosuppressant that significantly improves PASI 75 versus placebo when used in combination regimens.^[21] Despite modest efficacy compared to biologics, methotrexate remains widely used due to low cost and oral dosing. It requires regular liver enzyme and blood count monitoring.
• Cyclosporine: A calcineurin inhibitor recommended as a short-term option for extensive disease and as a second-line systemic in elderly patients with severe psoriasis.^[22] Long-term continuous use is not recommended because of nephrotoxicity and hypertension risk.^[49]
• Acitretin: An oral retinoid and prototypical retinoic acid analog that modulates epidermal keratinization. It is a first-line treatment for generalized pustular psoriasis, where it significantly reduces severity scores and inflammatory markers.^[23] Teratogenicity restricts its use in women of childbearing potential.

Newer Oral Agents: Apremilast and Deucravacitinib

Newer oral agents offer targeted mechanisms with fewer monitoring requirements:

• Apremilast (Otezla): A PDE4 inhibitor that reduces production of TNF-alpha, IL-17, and IL-23. It is well tolerated overall, though gastrointestinal side effects (nausea, diarrhea) are common early in treatment.^[24]
• Deucravacitinib (Sotyktu): A first-in-class TYK2 inhibitor approved in 2022. In a 52-week post hoc analysis of the POETYK PSO-1 trial, deucravacitinib produced 50% greater cumulative PASI 75 benefit than apremilast.^[25]

These oral options fill an important gap for patients who want systemic treatment without injections or intensive monitoring. But for the highest clearance rates, biologic therapies lead the field.

Biologic Therapies: The Most Effective Option for Severe Psoriasis

Biologics represent the most significant advance in psoriasis treatment in the past two decades. Unlike traditional systemics that broadly suppress the immune system, biologics target specific molecules in the inflammatory cascade.^[38] The result is higher efficacy with a more focused safety profile. For a detailed look at each agent, see our guide to biologic drugs for inflammatory skin disease.

How Biologics Target the Immune Pathway

Each biologic class blocks a different point in the psoriatic inflammation pathway. The first biologics used in psoriasis were anti-TNF therapies (adalimumab, etanercept, infliximab), but they generally produce lower complete-clearance rates than newer IL-17 and IL-23 inhibitors.^[26] Newer agents target the IL-23/IL-17 axis more selectively:

• IL-12/23 inhibitor (ustekinumab): Blocks the shared p40 subunit of IL-12 and IL-23.
• IL-17 inhibitors (secukinumab, ixekizumab, brodalumab, bimekizumab): Target IL-17A or its receptor, directly blocking the cytokine most responsible for keratinocyte proliferation.^[27] Bimekizumab also blocks IL-17F.^[30]
• IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab): Block the p19 subunit of IL-23, cutting off the upstream signal that drives Th17 cell activation.^[28]

The trend in biologic development has moved upstream in the inflammatory pathway. IL-23 inhibitors target the root signal rather than downstream effectors, and by stabilizing tissue-resident memory T cells, this approach may not only clear active lesions but also reduce relapse risk and promote more durable remission.^[29]

Comparing Biologic Classes

Biosimilars for adalimumab, etanercept, and infliximab have expanded access and reduced costs for TNF-alpha inhibitor therapy, with budget impact analyses showing potential savings of millions of dollars across patient populations.^[31] Patients managing psoriasis alongside other inflammatory conditions may also find our guide on psoriasis vs eczema useful for understanding how treatment strategies differ.

Biologics deliver the highest clearance rates available, but not everyone needs or wants systemic therapy. For mild to moderate psoriasis, over-the-counter options play a larger role than most people realize, often making the difference between flares that linger and skin that stays calm.

Over-the-Counter Psoriasis Treatment Options

Over-the-counter products form the daily foundation of psoriasis management at every severity level, and even patients on biologics benefit from consistent OTC care. Yet most guides lump all OTC options into a single paragraph. In reality, these products fall into distinct categories with very different functions, and knowing which does what helps you build a routine that actually works.

Moisturizers and Emollients: The Daily Foundation

Regular emollient use reduces scaling, itching, and the frequency of flares. For a science-backed overview of how different moisturizer types work, see our guide on how moisturizers work. In a multicenter RCT, adding a linoleic acid-ceramide moisturizer to mometasone furoate cream raised the PASI 50 response rate from 40% to 65% at week 8 and significantly reduced relapse.^[32] Our guide on science-backed ways to add moisture to your skin covers the best application techniques.

Thick, fragrance-free creams and ointments work best. Ceramide-containing moisturizers help restore the impaired skin barrier in psoriatic skin, where ceramide levels are reduced proportionally to PASI scores.^[32] Apply within minutes of bathing to lock in moisture.

Moisturizers alone do not treat the underlying inflammation, since they manage symptoms and support barrier function rather than calming the immune response. That is why they work best alongside active anti-inflammatory treatments.

OTC Medicated Products: Coal Tar, Salicylic Acid, Hydrocortisone

• Coal tar: One of the oldest psoriasis treatments. Coal tar has anti-inflammatory, antibacterial, antipruritic, and antimitotic effects, and acts as a photosensitizer that synergizes with UVB light.^[33] The main setbacks are its unfavorable smell, ability to stain fabric, and potential to cause contact dermatitis.
• Salicylic acid: A keratolytic that solubilizes intercellular cement in the stratum corneum, reducing corneocyte cohesion and promoting desquamation. Intermediate concentrations (3 to 6%) are commonly used for hyperkeratotic disorders including psoriasis.^[34] It treats the scale but not the underlying inflammation.
• OTC hydrocortisone (1%): The weakest topical steroid available. While it can reduce mild redness and itch, 1% hydrocortisone is generally too weak to penetrate established psoriatic plaques.^[13]

Each of these OTC options addresses only one aspect of psoriasis management. Moisturizers hydrate. Keratolytics remove scale. Weak steroids mildly reduce inflammation. None combines all three functions.

SmartLotion: The All-in-One Prebiotic Anti-Inflammatory Approach

SmartLotion takes a different approach by combining anti-inflammatory, prebiotic, and moisturizing functions in a single formulation. Developed by a board-certified dermatologist with over 30 years of clinical experience, this cream for psoriasis uses low-dose hydrocortisone enhanced by a prebiotic base containing sulfur and ingredients that support the skin's natural microbiome. To learn more about how sulfur works as an anti-inflammatory and antimicrobial agent in skin care, see our guide on sulfur as a treatment for psoriasis.

The prebiotic angle matters because the skin microbiome in psoriatic plaques is markedly altered, with reduced diversity and overgrowth of opportunistic pathogens like Staphylococcus aureus, Candida albicans, and Malassezia.^[35] For a deeper look at how the skin microbiome affects inflammatory conditions, see our guide on what the microbiome is. By supporting a healthier microbial environment, SmartLotion addresses a dimension of psoriasis management that other OTC products ignore.

The low-dose steroid component provides anti-inflammatory action, while the formulation's design allows for long-term daily use without the thinning and rebound concerns associated with higher-potency steroids. It is safe across all ages and body areas, including sensitive skin like the face and folds where stronger steroids cause trouble.

Treating Psoriasis in Special Locations and With Joint Involvement

Anyone who has tried to comb through scalp scale before a meeting, or hidden their hands in their pockets at a dinner, knows that psoriasis does not behave the same everywhere on your body. Location matters because hard-to-treat areas like the scalp, nails, face, and genitals carry an outsized impact on quality of life even when they cover only a small patch of skin, and they are linked to higher rates of depression than the same amount of disease elsewhere.^[11]

Hard-to-Treat Areas: Scalp, Nails, Face, Genitals

Scalp involvement affects 45 to 56% of psoriasis patients, with up to 90% experiencing it at some point, and thick plaques hidden under hair resist standard creams because hair blocks the medication from reaching the skin.^[36] Medicated shampoos containing coal tar or salicylic acid help mild cases, while moderate-to-severe scalp psoriasis often requires corticosteroid solutions or foams plus calcipotriene solution.^[13] Readers dealing with scalp symptoms may also find our scalp eczema treatment guide useful for comparing approaches across inflammatory scalp conditions, and our article on whether to cut your hair with psoriasis addresses common styling concerns.

Nail psoriasis has a lifetime incidence of 80 to 90%, with 23 to 27% of patients having nail involvement at any given time, and it is more prevalent in those with psoriatic arthritis.^[37] Pitting (small dents in the nail), onycholysis (separation of the nail from the nail bed), and subungual hyperkeratosis (buildup of scaly tissue under the nail) are hallmark signs that respond poorly to topicals alone. For scalp-specific treatment, see the scalp psoriasis protocol. For specific treatment approaches to intertriginous areas, see the flexure psoriasis protocol. For guttate management, our guttate psoriasis guide and the guttate treatment protocol provide detailed guidance.

When Psoriasis Affects Your Joints

Roughly 20 to 30% of people with psoriasis develop psoriatic arthritis (PsA), an inflammatory joint disease that can cause permanent damage if untreated.^[52] Delays in diagnosis and treatment are associated with poor radiographic and functional outcomes.^[39]

The presence of PsA changes treatment strategy. EULAR recommendations endorse biologics targeting TNF, IL-17A, or IL-12/23 when peripheral arthritis fails conventional DMARDs, with IL-17 preferred when there is significant skin involvement.^[40] If you notice joint symptoms, early rheumatology referral can prevent irreversible damage.

Building Your Treatment Plan and Knowing When to Escalate

If you have ever felt overwhelmed staring at the long list of psoriasis treatments, the simplest way to think about it is as a ladder. You start with the least invasive options and escalate based on response, and at every rung, consistent moisturizing and OTC care form the base. Natural and complementary approaches have a place too, though no natural option matches prescription therapies for moderate-to-severe disease.

The Treatment Ladder by Severity

Complementary approaches can supplement, not replace, this ladder. Salt bath plus UVB may improve psoriasis compared to UVB alone (risk ratio 1.71 in pooled trials), simulating Dead Sea balneotherapy.^[41] Fish oil supplementation, however, did not significantly reduce PASI scores in a meta-analysis of 13 RCTs and is not supported as a psoriasis treatment.^[42] Vitamin D deficiency is more common in psoriasis patients and correlates with disease severity, though evidence for oral supplementation is weaker than for topical vitamin D analogues.^[43] Aloe vera shows limited and inconsistent evidence,^[44] and probiotics may improve psoriasis symptoms in early studies but data remain preliminary.^[45]

Realistic Response Timelines

One of the biggest sources of frustration is not knowing when to expect results. Every treatment class has a different timeline:

When to Escalate or See a Dermatologist

Consider stepping up your treatment approach in the situations below. For guidance on building a complete daily skin care routine alongside prescription treatment, see Dr. Harlan's psoriasis protocol:

• Inadequate response: DLQI ≥ 5 and/or PASI ≥ 10 after a full treatment course^[46]
• Expanding disease: New plaques appearing despite treatment
• Quality-of-life impact: DLQI scores above 10 indicate a large effect on daily living and warrant treatment change^[47]
• Joint symptoms: Any signs of psoriatic arthritis warrant systemic treatment discussion
• High-impact locations: Face, hands, feet, or genital involvement that topicals cannot control

You should see a dermatologist if your psoriasis covers more than 3% of your body, affects high-impact areas, causes joint pain, significantly impacts quality of life, has not responded to OTC treatments after 4 to 8 weeks, or shows signs of infection. For a complete overview of how psoriasis is classified and diagnosed, see our psoriasis guide. Treatment escalation is not failure. Psoriasis is a chronic condition that often requires adjustment over time, and shorter disease duration is itself a predictor of super-responder status to modern biologics.^[38]

Frequently Asked Questions About Psoriasis Treatment

What is the best treatment for psoriasis?

The best psoriasis treatment depends on your severity. For mild disease, topical corticosteroids combined with vitamin D analogues remain the gold standard, while for moderate to severe psoriasis, IL-17 and IL-23 inhibitor biologics deliver the highest PASI 90 clearance rates of any therapy class.^[27] For daily OTC management at any severity level, SmartLotion offers an all-in-one anti-inflammatory, prebiotic, and moisturizing approach that supports your skin between prescription treatments.

What is the best over-the-counter cream for psoriasis?

Most OTC psoriasis products address only one symptom: moisturizers hydrate, coal tar reduces itch, salicylic acid removes scale. SmartLotion is the most complete OTC option because it combines anti-inflammatory, prebiotic, and moisturizing functions in one psoriasis cream. Its prebiotic base supports the skin microbiome, which research shows is disrupted in psoriatic skin.^[35] It is safe for daily long-term use on all body areas.

How long does psoriasis treatment take to work?

Response timelines vary by treatment type. Topical treatments show initial improvement in 2 to 4 weeks, with full effect at 8 to 12 weeks. Phototherapy takes 6 to 12 weeks of regular sessions. Oral systemics require 8 to 16 weeks. Biologics typically reach their primary response at 12 to 16 weeks, with continued improvement beyond that point.^[27]

Can psoriasis go away on its own?

Psoriasis is a chronic condition that rarely resolves completely without treatment. Spontaneous remission can occur, particularly with guttate psoriasis following streptococcal infection, where remission may happen within 3 to 4 months in some cases.^[48] However, in 40 to 50% of guttate cases the disease progresses to chronic plaque psoriasis, and plaque psoriasis typically persists and requires ongoing management.

References

1. Ponikowska M, Vellone E, Czapla M, Uchmanowicz I. "Challenges Psoriasis and Its Impact on Quality of Life: Challenges in Treatment and Management." Psoriasis (Auckland, N.Z.). 2025. View Study
2. Tveit KS, Duvetorp A, Østergaard M, et al. "Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP)." Journal of the European Academy of Dermatology and Venereology. 2019. View Study
3. Balato A, Burlando M, Campanati A, et al. "Strategies for Optimal Use of Biological Therapies in Managing Psoriasis: Focus on Secukinumab." Dermatology and Therapy. 2025. View Study
4. Lowes MA, Suárez-Fariñas M, Krueger JG. "Immunology of Psoriasis." Annual Review of Immunology. 2014. View Study
5. Wu Z, Wang R, Liu Y, Yang B, Wang H. "RNA Sequencing Reveals That the Genes Related to Cell Cycle and Glycolysis Play an Essential Role in IL-27-Induced Keratinocyte Hyperproliferation." Journal of Inflammation Research. 2024. View Study
6. Korman NJ. "Management of psoriasis as a systemic disease: what is the evidence?" British Journal of Dermatology. 2021. View Study
7. Liu T, Li S, Ying S, Tang S, Ding Y, Li Y, Qiao J, Fang H. "The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside." Frontiers in Immunology. 2020. View Study
8. Veerasubramanian PK, Wynn TA, Quan J, Karlsson FJ. "Targeting TNF/TNFR superfamilies in immune-mediated inflammatory diseases." The Journal of Experimental Medicine. 2024. View Study
9. von Stebut E, Boehncke WH, Ghoreschi K, et al. "IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications." Frontiers in Immunology. 2020. View Study
10. Strober B, Patel M, Kaldas MI, et al. "Real-World Skin Clearance and Quality of Life with risankizumab in Patients with Psoriasis with Moderate Skin Involvement and Those Eligible for Systemic Therapy Per International Psoriasis Council Classification." Dermatology and Therapy. 2025. View Study
11. Lupulescu AM, Savu AP, Bucur Ş, Şerban ED, Popescu S, Constantin MM. "Hard-to-Treat Areas in Psoriasis: An Underevaluated Part of the Disease." Life (Basel). 2025. View Study
12. Goddard EJ, Haughton JM, Lucas JE, et al. "Patient Disease Characteristics and Treatment Patterns in Mild-Moderate Psoriasis: Results from Real-World Clinical Practice in the United States (PROSPECT Study)." Dermatology and Therapy. 2025. View Study
13. Schlager JG, Rosumeck S, Werner RN, et al. "Topical treatments for scalp psoriasis." Cochrane Database of Systematic Reviews. 2016. View Study
14. Flori E, Mosca S, Kovacs D, et al. "Skin Anti-Inflammatory Potential with Reduced Side Effects of Novel Glucocorticoid Receptor Agonists." International Journal of Molecular Sciences. 2024. View Study
15. Ashcroft DM, Li Wan Po A, Williams HC, Griffiths CEM. "Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis." BMJ. 2000. View Study
16. Licata G, Arisi M, Venturini M, et al. "Pretreatment with an Aerosol Foam Containing Calcipotriene and Betamethasone Strongly Improves the Efficacy of Narrow-Band UVB Phototherapy." Dermatology and Therapy. 2022. View Study
17. Igarashi A, Tsuji G, Fukasawa S, Murata R, Yamane S. "Tapinarof cream for the treatment of plaque psoriasis: Efficacy and safety results from 2 Japanese phase 3 trials." The Journal of Dermatology. 2024. View Study
18. Lebwohl MG, Kircik LH, Moore AY, et al. "Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials." JAMA. 2022. View Study
19. Deeni YY, Ibbotson SH, Woods JA, Wolf CR, Smith G. "Cytochrome P450 CYP1B1 Interacts with 8-Methoxypsoralen (8-MOP) and Influences Psoralen-Ultraviolet A (PUVA) Sensitivity." PLoS One. 2013. View Study
20. Myers E, Kheradmand S, Miller R. "An Update on Narrowband Ultraviolet B Therapy for the Treatment of Skin Diseases." Cureus. 2021. View Study
21. Nayak S, Zafar S, Herve N, Siri P, Ali KH. "Efficacy and safety of various drug combinations in treating plaque Psoriasis: A meta-analysis." F1000Research. 2025. View Study
22. Oon HH, Tan C, Aw DCW, et al. "2023 guidelines on the management of psoriasis by the Dermatological Society of Singapore." Annals of the Academy of Medicine, Singapore. 2024. View Study
23. Shen S, Tang X, Wang W, et al. "Transcriptomic landscape of generalized pustular psoriasis before and after acitretin/glucocorticoids treatment." Clinical and Experimental Medicine. 2025. View Study
24. Elsisi AE, Abu-Risha SE, Alkabbani MA, Ramadan LA, Sokar SS. "Balancing efficacy and hepatotoxicity: a comprehensive review of oral medications in psoriasis management." Naunyn-Schmiedeberg's Archives of Pharmacology. 2025. View Study
25. Armstrong AW, Park SH, Patel V, et al. "Cumulative Benefit Over 52 Weeks With Deucravacitinib Versus Apremilast in Moderate to Severe Plaque Psoriasis: POETYK PSO-1 Post Hoc Analysis." Dermatology and Therapy. 2024. View Study
26. Sawyer LM, Malottki K, Sabry-Grant C, et al. "Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response." PLoS One. 2019. View Study
27. Sbidian E, Chaimani A, Garcia-Doval I, et al. "Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis." Cochrane Database of Systematic Reviews. 2022. View Study
28. Li Zhou, Yibing Wang, Qi Wan, et al. "A non-clinical comparative study of IL-23 antibodies in psoriasis." mAbs. 2021. View Study
29. Megna M, D'Agostino M, Feo F, et al. "IL-23 Inhibitors in Psoriasis: What Have We Learnt so Far?" Journal of Inflammation Research. 2026. View Study
30. Armstrong A, Fahrbach K, Leonardi C, et al. "Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis." Dermatology and Therapy. 2022. View Study
31. Gisondi P, Bellinato F, Curic T, Girolomoni G. "Biosimilars for the Treatment of Moderate to Severe Chronic Plaque Psoriasis." Psoriasis (Auckland, N.Z.). 2025. View Study
32. Li X, Yang Q, Zheng J, et al. "Efficacy and safety of a topical moisturizer containing linoleic acid and ceramide for mild-to-moderate psoriasis vulgaris: A multicenter randomized controlled trial." Dermatologic Therapy. 2020. View Study
33. Rattanakaemakorn P, Triyangkulsri K, Iamsumang W, Suchonwanit P. "308-nm Excimer Lamp vs. Combination of 308-nm Excimer Lamp and 10% Liquor Carbonis Detergens in Patients With Scalp Psoriasis: A Randomized, Single-Blinded, Controlled Trial." Frontiers in Medicine. 2021. View Study
34. Dampa E. "The Effectiveness of Topical Keratolytics (Alpha Hydroxy Acids/Beta Hydroxy Acids/Urea) in Treating Keratosis Pilaris: A Review of the Literature." Cureus. 2025. View Study
35. Sabry HH, Noor ZS, Elsayed RAH, Nazmy NN. "Association of skin microbiome with interleukin-23 in patients with plaque psoriasis." Postepy Dermatologii i Alergologii. 2025. View Study
36. Dopytalska K, Sobolewski P, Błaszczak A, Szymańska E, Walecka I. "Psoriasis in special localizations." Reumatologia. 2018. View Study
37. Elewski BE, Blauvelt A, Gallo G, et al. "Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis." Dermatology and Therapy. 2022. View Study
38. Di Giulio S, Falcidia C, Foggi G, et al. "Predictors of Super-Responder Status to Anti-IL-23 Therapies in Moderate-to-Severe Plaque Psoriasis: A Real-World Monocenter Study." Journal of Clinical Medicine. 2025. View Study
39. Belasco J, Wei N. "Psoriatic Arthritis: What is Happening at the Joint?" Rheumatology and Therapy. 2019. View Study
40. Gossec L, Baraliakos X, Kerschbaumer A, et al. "EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update." Annals of the Rheumatic Diseases. 2020. View Study
41. Peinemann F, Harari M, Peternel S, et al. "Indoor salt water baths followed by artificial ultraviolet B light for chronic plaque psoriasis." Cochrane Database of Systematic Reviews. 2020. View Study
42. Yang SJ, Chi CC. "Effects of fish oil supplement on psoriasis: a meta-analysis of randomized controlled trials." BMC Complementary and Alternative Medicine. 2019. View Study
43. Bhat GH, Guldin S, Khan MS, Yasir M, Prasad G. "Vitamin D status in Psoriasis: impact and clinical correlations." BMC Nutrition. 2022. View Study
44. Vogler BK, Ernst E. "Aloe vera: a systematic review of its clinical effectiveness." The British Journal of General Practice. 1999. View Study
45. Zeng L, Yang K, He Q, et al. "Efficacy and safety of gut microbiota-based therapies in autoimmune and rheumatic diseases: a systematic review and meta-analysis of 80 randomized controlled trials." BMC Medicine. 2024. View Study
46. Valenti M, Ibba L, Cascio Ingurgio R, et al. "A 3-Year Multicentric Study on Switching from Ustekinumab to Guselkumab in Partial Responders with Psoriasis—IL PSO (Italian Landscape Psoriasis)." Dermatology and Therapy. 2024. View Study
47. Chernyshov PV, Marron SE, Boffa MJ, et al. "Sensitivity to treatment and score bands of the Infants and Toddlers Dermatology Quality of Life questionnaire." JAAD International. 2023. View Study
48. Leung AKC, Barankin B, Lam JM, Leong KF. "Childhood guttate psoriasis: an updated review." Drugs in Context. 2023. View Study
49. Park KK, Park JH, Jung YJ, Lee JH. "The Advantage of Cyclosporine A and Methotrexate Rotational Therapy in Long-Term Systemic Treatment for Chronic Plaque Psoriasis in a Real World Practice." Annals of Dermatology. 2017. View Study
50. Salgado-Boquete L, Carrascosa JM, Llamas-Velasco M, Ruiz-Villaverde R, de la Cueva P, Belinchón I. "A New Classification of the Severity of Psoriasis: What's Moderate Psoriasis?" Life (Basel). 2021. View Study
51. van Nies JAB, Alves C, Radix-Bloemen ALS, et al. "Reappraisal of the diagnostic and prognostic value of morning stiffness in arthralgia and early arthritis: results from the Groningen EARC, Leiden EARC, ESPOIR, Leiden EAC and REACH." Arthritis Research & Therapy. 2015. View Study
52. Ocampo D V, Gladman D. "Psoriatic arthritis." F1000Research. 2019. View Study